TrialInvestigational new drugs2025

A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors.

Hoi Wai Chan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.